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Abstract
Background: The fatty acid mixture of human milk is ideal for the newborn but little is known about its
composition in the first few weeks of lactation. Of special interest are the levels of long-chain PUFAs (LCPUFAs),
since these are essential for the newborn’s development. Additionally, the LCPUFAs arachidonic acid (AA),
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are precursors for lipid mediators which regulate
inflammation.
Methods: We determined the composition of 94 human milk samples from 30 mothers over the first month of
lactation for fatty acids using GC-MS and quantified lipid mediators using HPLC-MS/MS.
Results: Over the four weeks period, DHA levels decreased, while levels of γC18:3 and αC18:3 steadily increased.
Intriguingly, we found high concentrations of lipid mediators and their hydroxy fatty acid precursors in human milk,
including pro-inflammatory leukotriene B4 (LTB4) and anti-inflammatory and pro-resolving lipoxin A4 (LXA4),
resolvin D1 (RvD1) and resolvin E1 (RvE1). Lipid mediator levels were stable with the exception of two direct
precursors.
Conclusions: Elevated levels of DHA right after birth might represent higher requirements of the newborn and the
high content of anti-inflammatory and pro-resolving lipid mediators and their precursors may indicate their role in
neonatal immunity and may be one of the reasons for the advantage of human milk over infant formula.
Keywords: Human milk, Omega-3 fatty acids, DHA, EPA, 17-HDHA, 18-HEPE, 15-HETE, Resolvins, Lipoxins,
Leukotrienes
Background
Human milk fat is the main energy source for the
breast-fed newborn and provides specific fatty acids that
are required for the newborn’s development. The fatty
acid composition of human milk has been assessed in
several studies showing differences between term and
preterm milk [1-5] and the influence of diet on the fatty
acid composition [6-8]. There is also indication for a
change in fatty acid composition over the lactation
period [5,9-18].
Especially, LCPUFAs fulfill several essential functions
in the newborns. For example, the omega-6 LCPUFA
AA and the omega-3 LCPUFA DHA are crucial for brain
and nervous system development [19,20], the visual
system [21] and for early human growth in general [22].
In addition, the fatty acid profile of human milk has
been associated with the development of atopy and with
allergic diseases in children [23-26].
The supply of LCPUFAs by human milk to the new-
born determines the fatty acid composition of several
lipid compartments including plasma lipids and the
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cellular membrane [27]. The fatty acid composition of the
membrane influences not only membrane properties but
also immune-regulatory processes through the meta-
bolization of free and membrane bound LCPUFAs to lipid
mediators [28]. These lipid mediators are signaling mole-
cules that initiate and resolve inflammation and they
derive from oxygenation of the omega-6 fatty acid AA and
the two omega-3 fatty acids DHA and EPA [29,30].
Oxygenation of AA, DHA and EPA occurs in a con-
certed action of lipoxygenases, cyclooxygenases and
cytochrome-P-450 dependent oxygenases to result in the
pro-inflammatory leukotrienes and the anti-inflammatory
lipoxins from AA and resolvins and protectins from DHA
and EPA [29-34]. Apart from being anti-inflammatory,
lipoxins, resolvins and protectins also initiate inflamma-
tion-resolving actions like recruitment of nonphlogistic
monocytes and clearance of apoptotic polymorphonuclear
neutrophils by macrophages [35-37]. Due to their potent
immune-regulatory functions, these lipid mediators are
thought to play a role in chronic inflammatory diseases like
atherosclerosis, rheumatoid arthritis and inflammatory
bowel disease [31,38-40]. We therefore surmised that a sup-
ply of anti-inflammatory and pro-resolving lipid mediators
to the newborn by breast milk could be one of the explana-
tions for the lower incidence of intestinal inflammation in
breast-fed compared to formula-fed infants [41,42].
Only limited information is available on the fatty acid
composition of human milk over the first few weeks of
lactation [15-18], and the presence of leukotrienes,
lipoxins and resolvins in human milk has not been
investigated yet. In this study, we present the milk fatty
acid profile and the profile for selected bioactive lipid
mediators and their precursors in human milk over the
first month of lactation.
Results
Quantification of fatty acid composition in human milk
Thirteen fatty acids containing 16 to 24 carbon atoms
(Table 1 and Figure 1) were analysed and quantified in
human milk with a specific and selective GC-MS
method. For each analyte, the calibration was linear with
R2 >0.98 and the observed fatty acid concentrations in
breast milk were within the working range (See Additional
file 1: Table S1). Intra-assay coefficients of variation are
stated in (Additional file 1: Table S1).
Fatty acid composition of human milk over the first
month of lactation
The lactational age of the collected human milk samples
ranged from 1 to 30 days postpartum. For statistical
analysis, the samples were divided into six groups
according to their lactational age (Table 2). The major
fatty acids in human milk were C18:1, C16:0, C18:2 and
C18:0 in descending order. Other fatty acids were
present with quantities lower than 5% of total fatty acids.
The relative content was stable over the first month of
lactation for the saturated fatty acids C16:0 to C22:0.
Only C24:0 showed a significant decrease (Table 2). The
amounts of the monounsaturated fatty acids C16:1 and
C18:1 were stable over the observed time period. In
contrast, the amount of most PUFAs changed over time
(Figure 2). The amount of DHA decreased to approxi-
mately half of the initial quantity (p < 0.0001, Table 2),
while its precursor αC18:3 increased over the same
period. Similarly, the amount of AA showed a trend to
decrease over time (p=0.094) while its precursor γC18:3
increased. Albeit these changes in the concentration of
the PUFAs, the ratio of omega-6 (C18:2, γC18:3, AA) to
omega-3 (αC18:3, EPA, DHA) fatty acids in human milk
did not change significantly over the first four weeks of
lactation.
Quantification of selected lipid mediators and precursors
in human milk
To determine the concentration of the selected lipid
mediators in human breast milk, a HPLC-MS/MS
method was developed analyzing LTB4, LXA4, RvE1 and
RvD1 and the four hydroxy fatty acids 17-hydro-
xydocosahexaenoic acid (17-HDHA), 18-hydroxyeico-
sapentaenoic acid (18-HEPE), 15-hydroxyeicosatetraenoic
acid (15-HETE) and 12-hydroxyeicosatetraenoic acid (12-
HETE) (Figures 3 and 4). For each compound, several
transitions were scanned (See Addtional file 1: Table S2)
and one transition per analyte was selected as quantifier
ion. For each lipid mediator and hydroxy fatty acid, the
fragmentation pattern of the analyte from human milk was
comparable to the fragmentation pattern of the corre-
sponding standard substance (See Additional file 2: Figure
Table 1 Fatty acids analyzed in human milk
State of saturation Fatty acid Lipid number
(C:D)a
Saturated Palmitic acid C16:0
Stearic acid C18:0
Arachidic acid C20:0
Behenic acid C22:0
Lignoceric acid C24:0
Monounsaturated Palmitoleic acid C16:1
Oleic acid C18:1
Omega-6 polyunsaturated Linoleic acid C18:2
γ-Linolenic acid γC18:3
Arachidonic acid C20:4
Omega-3 polyunsaturated α-Linolenic acid αC18:3
Eicosapentaenoic acid C20:5
Docosahexaenoic acid C22:6
a C, number of carbon atoms; D, number of double bonds
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Figure 1 Gas-chromatogram of fatty acid standard substances. Fatty acids in standard mixture were methylated according to the sample
preparation procedure prior to injection into the GC-MS system. For nomenclature of the fatty acids see Table 1.
Table 2 Total fatty acid composition (%) of human milk over time of lactation
Fatty acid Time of lactation (days after birth) R2 P
1-5 6-10 11-15 16-20 21-25 26-30
N=15 N=27 N=23 N=16 N=6 N=7
M M M M M M
SD SD SD SD SD SD
C16:0 23.96 20.75 21.96 21.95 21.90 21.92 0.12 0.63
3.47 2.41 2.55 2.59 2.60 4.02
C18:0 6.91 6.06 7.73 7.34 6.85 7.64 0.23 0.37
1.59 1.31 1.90 1.69 0.67 1.36
C20:0 0.17 0.11 0.15 0.14 0.12 0.12 0.36 0.10
0.06 0.03 0.04 0.05 0.03 0.03
C22:0 0.22 0.13 0.15 0.12 0.13 0.17 0.16 0.27
0.18 0.04 0.06 0.04 0.04 0.03
C24:0 0.29 0.17 0.20 0.16 0.14 0.18 0.48 0.011
0.12 0.07 0.10 0.09 0.05 0.05
C16:1 3.35 4.55 3.66 4.30 4.27 3.67 0.02 0.74
0.87 1.35 1.17 1.81 1.21 0.89
C18:1 46.29 48.21 45.76 44.92 46.26 43.96 0.46 0.51
5.42 3.94 5.28 3.80 5.17 2.50
C18:2 14.42 16.10 16.58 17.16 16.72 18.43 0.83 0.13
3.09 3.24 3.97 3.37 3.45 2.80
γC18:3 0.09 0.10 0.10 0.11 0.11 0.13 0.81 0.040
0.03 0.02 0.04 0.04 0.02 0.02
C20:4 (AA) 2.09 1.82 1.56 1.79 1.49 1.48 0.73 0.094
0.96 0.91 0.62 0.83 0.41 0.49
αC18:3 1.07 1.04 1.41 1.34 1.47 1.82 0.85 0.0024
0.44 0.23 0.62 0.58 0.33 0.48
C20:5 (EPA) 0.08 0.06 0.06 0.07 0.07 0.07 0.06 0.77
0.02 0.02 0.03 0.01 0.02 0.01
C22:6 (DHA) 1.15 0.99 0.79 0.71 0.59 0.56 0.96 <0.0001
0.42 0.33 0.25 0.32 0.11 0.22
n6/n3 7.58 8.92 8.31 9.47 8.81 8.27 0.12 0.59
1.73 2.40 1.50 3.11 2.53 1.00
M, mean % of total fatty acids; SD, standard deviation; R2, coefficient of determination of linear trendline; P, p-value for linear trend (ANOVA)
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S1, and Additional file 3: Figure S2). For each analyte, the
calibration was linear with R2 >0.98 and the observed lipid
mediator concentrations in breast milk were within the
working range. Intra-assay coefficients of variation are
stated in (Additional file 1: Table S2).
Lipid mediator concentrations of human milk over the
first month of lactation
The breast milk concentration of the lipid mediators
LTB4, LXA4, RvE1 and RvD1 showed mean values (and
ranges) of 9 ng/ml (0.01 to 24.5 ng/ml) for LTB4, 21 ng/
ml (0.1 to 54.1 ng/ml) for LXA4, 6 ng/ml (0.03 to 41.5
ng/ml) for RvE1 and 10 ng/ml (0.01 to 44.5 ng/ml) for
RvD1, and was stable over the period of one month for
all lipid mediators (Table 3). The mean concentrations
of the precursor hydroxy fatty acids were higher than
the concentrations of the more bioactive forms with the
exception of 18-HEPE, which was observed at similar
concentrations to the resulting lipid mediator RvE1 at
the beginning of lactation. Over the observed four weeks
of lactation, 18-HEPE increased in concentration, al-
though not significantly (p=0.063). In contrast, the
Figure 2 Changes in omega-6 and omega-3 fatty acids in human milk over the first month of lactation. Relative amount of the omega-6
PUFA (E) AA (C20:4) and its precursors (A) C18:2 and (C) γC18:3. Relative amount of the omega-3 PUFA (F) DHA (C22:6) and its precursors (D)
αC18:3 and (B) EPA (C20:5). For an overview on PUFA fatty acid biosynthesis see Figure 3.
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17-HDHA content of human breast milk decreased. It
was more than three times higher in the first five days
postpartum than three weeks postpartum (Figure 5),
which followed the change in DHA content of the
human breast milk. The concentrations of 12-HETE and
15-HETE were stable over the observed time period.
Discussion
In this study, we examined the fatty acid and the derived
lipid mediator profiles of human breast milk over the first
month of lactation. While most of the fatty acids showed
stable concentrations over the four weeks of lactation,
the concentrations of the omega-6 fatty acid AA and
of the omega-3 fatty acid DHA decreased over time.
Concomitantly, the amount of the precursor fatty acids for
both of these very long-chain PUFAs increased. Human
breast milk also contains a considerable amount of
lipid mediators and its precursor hydroxy fatty acids. While
we did not observe a change in concentration for the lipid
mediators over the investigated lactation period, the
DHA metabolite 17-HDHA decreased in parallel to
the DHA concentration (See Additional file 1: Table S3).
The most surprising finding of this study was the high
concentration of bioactive lipid mediators and their
precursors in human milk. The levels of these analytes
in human milk have not been reported so far. All of the
investigated lipid mediators LTB4, LXA4, RvE1 and
RvD1 were found at considerable concentrations, which
were higher than the concentrations reported for plasma
of healthy individuals. While human breast milk con-
tains in average 8 ng/ml of the pro-inflammatory LTB4,
the level for LTB4 was reported to be 100 times lower in
plasma with concentrations of approximately 34 pg/ml
[43]. Similarly, the concentration for the anti-inflamma-
tory lipid mediators is higher in human breast milk.
While breast milk contains in average 18 ng/ml LXA4,
the plasma levels were reported to be 100 times lower
ranging from 10 to 26 pg/ml [44]. Also, RvD1 levels are
Figure 3 Simplified scheme for the biosynthesis of the selected
measured lipid mediators. LTB4, LXA4, RvE1 and RvD1 are
produced from the two essential omega-6 and omega-3 fatty acid
pathways via the corresponding intermediate mono-hydroxy
fatty acids.
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Weiss et al. Lipids in Health and Disease 2013, 12:89 Page 5 of 12
http://www.lipidworld.com/content/12/1/89
100 times lower in plasma than in human breast milk
with 31 pg/ml [45] and 9 ng/ml, respectively. The levels
for RvE1 are 10 times higher in human breast milk than
in plasma with 6 ng/ml and 0.1 to 0.4 ng/ml of RvE1,
respectively [33]. There is also a 10–100 times increase
in the concentration of the precursors for these lipid
mediators. While we detected 12-HETE, 15-HETE, 18-
HEPE and 17-HDHA mean concentrations in human
breast milk in the range of 5–40 ng/ml, these hydroxy
fatty acids were measured in the low nanomolar range in
human whole blood with concentrations ranging from
0.1 to 4.10 ng/ml [45,46]. Thus, there seems to be an
enrichment of the lipid mediators and its precursors in
human breast milk, similar to the enrichment previously
observed for some of the prostaglandins [47].
Our data also suggest a preferred accumulation of
anti-inflammatory and pro-resolving lipid mediators in
human milk as seen by the bioactive products of AA.
This fatty acid can be converted into pro- and anti-
inflammatory lipid mediators like LTB4 and LXA4, re-
spectively [48]. In human milk, the average content of
anti-inflammatory LXA4 is double as high as for the
Table 3 Concentration (ng/ml) of lipid mediators and precursors in human milk over time of lactation
Compound Time of lactation (days after birth) R2 P
1-5 6-10 11-15 16-20 21-25 26-30
N=11-14 N=20-23 N=20-21 N=13-14 N=6 N=6-7
M M M M M M
SD SD SD SD SD SD
LTB4 9.48 10.01 10.19 8.47 9.31 7.78 0.51 0.44
8.59 4.43 5.28 6.31 5.64 3.34
LXA4 15.55 25.02 22.11 16.65 19.53 22.04 0.02 0.19
16.87 14.68 13.11 14.06 10.11 12.60
RvE1 4.24 5.23 8.15 4.60 12.57 5.67 0.19 0.13
5.76 3.91 11.45 4.08 15.20 5.65
RvD1 9.42 12.46 12.37 6.48 9.53 9.99 0.08 0.58
11.68 7.34 9.28 6.24 4.64 5.06
17-HDHA 53.38 40.73 34.04 22.72 14.76 28.27 0.71 0.0035
37.80 25.41 22.61 20.94 6.61 25.50
18-HEPE 7.20 7.29 8.99 6.28 9.80 8.30 0.18 0.063
5.02 2.63 3.92 4.54 6.60 3.29
15-HETE 28.38 24.19 26.90 25.35 22.80 26.04 0.22 0.60
16.44 12.86 11.72 17.85 8.33 19.65
12-HETE 43.90 38.46 36.71 28.12 28.75 23.63 0.95 0.39
26.61 29.11 15.99 19.37 15.80 11.55
M, mean; SD, standard deviation; R2, coefficient of determination of linear trendline; P, p-value for linear trend (ANOVA)
Figure 5 Changes in the concentration of the precursor hydroxy fatty acids over the first month of lactation. Concentrations of (A)
18-HEPE (precursor of RvE1) and (B) 17-HDHA (precursor of RvD1) were measured in human milk over the first month of lactation.
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pro-inflammatory LTB4, while in human whole blood
the concentration of LXA4 seems to be lower than the
concentration of LTB4 [43,44]. In addition, there are
high concentrations of the precursor hydroxy fatty acids
for the anti-inflammatory and pro-resolving lipid media-
tors present in human breast milk. At least some of the
precursors also have potent anti-inflammatory and pro-
resolving effects, which may derive from a direct effect
or through its metabolism to the lipid mediators.
Several studies have shown that the lipid mediators
LXA4, RvE1 and RvD1 have potent anti-inflammatory
and pro-resolving effects in experimental mouse models
of intestinal colitis [49-53]. In addition, also 17-HDHA,
the precursor for RvD1, was shown to reduce inflamma-
tion in dextran sulfate sodium induced colitis in mice
[52]. It is therefore tempting to speculate that these high
levels of lipid mediators and their precursors in human
milk might affect the immune regulation of the gastro-
intestinal tract in the newborn. In this line, the concen-
trations measured in human breast milk for RvD1 and
LXA4 meet the concentrations necessary to effect human
leukocytes in an anti-inflammatory and pro-resolving
manner [54,55]. For example, LXA4 and RvE1 were shown
to suppress neutrophil infiltration and to promote phago-
cytosis of bacteria and apoptotic neutrophils by macro-
phages in the nanomolar range [33,35,56,57]. In similar
concentrations, analogs of LXA4 were able to reduce
pathogen-induced interleukin-8 production in intestinal
[58] and bronchial human epithelial cells [59], which
resulted in inhibited neutrophil recruitment, and thus in
reduced inflammation. Hence, the measured breast milk
concentrations of anti-inflammatory and pro-resolving
lipid mediators are within the physiological range reported
to inhibit inflammatory processes, and therefore, might
lower inflammation in the newborn infant.
The concentrations of the measured lipid mediators
did not change over the first month of lactation in
contrast to the two precursor hydroxy fatty acids 17-
HDHA and 18-HEPE. While the concentration of 18-
HEPE slightly increases during lactation, the concentra-
tion of 17-HDHA decreases in parallel to the decrease
of its precursor fatty acid DHA. The breast milk concen-
trations of the lipid mediator products RvE1 and RvD1
do not show the same temporal pattern, which is in
agreement with the just in time generation of these
inflammatory regulators during an acute inflammation
[48]. Similarly, the concentrations of all the lipid media-
tors investigated in this study are constant in breast milk
over the first month of lactation. Hence, an effect of
degradation during storage can be excluded, since all
samples were stored for the same time period. However,
it is not clear why the intermediate precursor fatty acids
investigated are present in such high concentrations in
human breast milk. Possibly, these fatty acids are
supplied as pre-metabolized lipid mediators for a final
conversion to the more potent lipid mediators in the
newborn’s intestine. Considering the high concentration
of these anti-inflammatory and pro-resolving hydroxy
fatty acids and lipid mediators in human breast milk, we
presume a potential role in lowering the overall inflam-
mation in breast-fed infants, suggesting a possible reason
for the lower incidence of inflammatory diseases in breast-
fed compared to formula-fed children [60-62]. In addition,
these lipid mediators may be involved in gastrointestinal
pain reception in newborns, since RvE1 and RvD1 have
been shown to reduce inflammatory pain in mice [63].
The average fatty acid profile found in our study is
similar to the fatty acid compositions reported before
[1,5,7,14,23,64]. Considering the profile over the first
month of lactation, the relative content in milk is stable
for most fatty acids, while the concentration of specific
LCPUFAs changes over this period.
Similar results were found in recent studies in which
human milk with equal lactational age was analyzed and
which presented the same decrease of DHA and AA
over time, while the precursor fatty acids C18:2, γC18:3
and αC18:3 increased during the same period [6,14]. It
was previously speculated that the increase in the
precursors C18:2, γC18:3 and αC18:3 might compensate
for the declining levels of DHA and AA in human breast
milk, which may come from the depletion of the mater-
nal DHA stores [65]. Alternatively, the high relative
amounts of DHA and AA in the beginning of lactation
may well be a mechanism to compensate for the lower
absolute fat content of human breast milk in the begin-
ning of lactation [64,66]. This may assure a stable supply
of DHA and AA to the newborn suggesting a regulation
of the fatty acid secretion by the mammary gland, which
is not only dependent on the maternal DHA intake and
plasma levels.
DHA and AA are important for the neonatal develop-
ment. Especially DHA has a high abundance in the
brain and retina where it is accumulated predominantly
in the last trimester of pregnancy and during the first
year after birth [67]. Before birth, most of the accumu-
lated DHA is delivered from the mother by transplacen-
tal transfer [68]. After birth, human milk is the only
exogenous source of DHA for the breast-fed child. The
endogenous de novo production of the newborn and the
DHA stores in adipose tissue alone are not sufficient to
maintain DHA homeostasis [69]. Infants fed formula
without DHA showed reduced DHA stores in their
tissue six months after birth and showed only half the
accumulation rate for DHA in the brain compared to
breast-fed infants [70]. At the same time, breast-fed
infants further increased their DHA stores also in non-
brain tissues. Hence, the newborn’s need for DHA is
eminent and elevated DHA levels in human milk right
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after birth may represent the high requirement for DHA
at that time.
Preterm infants are born with a lower DHA status,
because they did not complete intrauterine DHA accu-
mulation [71]. The importance of DHA for the develop-
ment is underlined by the higher DHA content of
human preterm milk [2] and by the elevated activity of
enzymes required for LCPUFA production in preterm
infants [72]. This suggests that the fatty acid compos-
ition of human milk is part of the natural mechanism to
regulate the infant’s DHA status.
DHA and AA are on the one hand vital for neuronal
and visual functions, and on the other hand pivotal for
the neonatal development of the immune system.
Several studies confirmed that the DHA status is linked
to various immune processes [73-77] and that several
LCPUFAs have the potential to influence the immune
system. For example, atopic sensitization of the newborn
is associated to the α-linolenic acid and omega-3 fatty
acid supply [78] and a higher tissue status of omega-3
fatty acids results in reduced inflammation and less
tissue injury in a colitis model in mice [79]. The latter
was shown in transgenic mice expressing fat-1, the
enzyme responsible for the endogenous production of
the omega-3 and omega-6 LCPUFAs DHA and AA
from the essential PUFAs. As mentioned before, these
LCPUFAs are the precursors of the lipid mediators
and the metabolism of these LCPUFAs to the correspond-
ing lipid mediators may play a role in the protective effect
of the LCPUFAs in innate and adaptive immune responses
[80-82]. Hence, our results suggest that human milk may
be an important regulator of neonatal immunity by pro-
viding not only the precursors, but also the bioactive
forms of these lipid mediators.
Conclusions
We investigated human milk to identify components
that are responsible for the beneficial effect of human
milk on neonatal health. Our results confirm a consider-
able amount of DHA and AA in human milk with
higher levels in the beginning of lactation. Since the nu-
trient composition of human milk reflects the ideal mix-
ture to satisfy the newborn’s needs, this likely mirrors
the neonatal DHA and AA requirements. Moreover, we
demonstrate the presence of bioactive lipid mediators in
human milk which affect atopy and inflammation and
therefore influence neonatal immunity. Our results sup-
port an addition of DHA and AA to infant formula
which is often done nowadays, but still is not standard
practice. The high content of anti-inflammatory lipid
mediators and its precursors in human breast milk may
indicate the crucial role of lipid mediators in neonatal
immunity and may be a reason for the advantage of hu-
man breast milk over infant formula.
Methods
Sample collection and preparation for fatty acid analysis
94 human milk samples were obtained from 30 mothers
and the lactational age was recorded. Samples were
stored at −20°C for approximately 120 days. Sample
preparation for total fatty acid analysis was essentially
done according to Moser et al. [83]. 125 μl of human
milk was diluted 1:2 with ultrapure water (ELGA
Purelab Ultra, Labtec Service AG, Wohlen, Switzerland)
and subjected to protein precipitation with 1 ml
methanol-methylene chloride (3:1, v/v). 20 μg d3-C17:0
(Cambridge Isotope Laboratories, Inc., Andover, MA,
USA) and 0.8 μg d3-C22:0 (Dr. Ehrenstorfer GmbH,
Augsburg, Germany) were added as internal standards.
Fatty acid methyl esters were prepared by the addition of
200 μl acetyl chloride and subsequent incubation at 75°C
for one hour. The reaction was neutralized with 4 ml
7% K2CO3, and fatty acid methyl esters were
extracted with 2 ml hexane. After centrifugation at
2500 rpm for 20 min, 1.6 ml of the hexane layer was
dried under nitrogen and redissolved in 280 μl heptane for
injection into the GC-MS system. Calibration curves
were obtained with defatted cow’s milk spiked with
known concentrations of fatty acid standards, thereby
defining the individual working range for each fatty
acid (See Additional file 1: Table S1).
GC-MS of fatty acid methyl esters
One μl sample was injected into a Finnigan PolarisQ ion
trap GC-MS system (Thermo Quest, Austin, TX, USA).
The injector temperature was 280°C and fatty acid
methyl esters were separated on a 30 m BGB-1701
column (BGB Analytik AG, Boeckten, Switzerland). The
initial oven temperature of 50°C was hold for 8 min and
then increased gradually by 5°C/min reaching a final
temperature of 280°C. The ion source temperature and
transfer line temperature was 230°C and 300°C,
respectively. Analytes were detected as positive ions in
full scan mode from 50 to 650 m/z. Specific mass traces
were extracted for the quantification of each analyte (See
Additional file 1: Table S1). Fatty acids were identified
by comparison of retention time and mass spectrum
with authentic standards.
Sample preparation for analysis of lipid mediators and
their precursors
85 of the human milk samples were stored at −20°C for
approximately 330 days. The analyte extraction method
was adapted from Yang et al. [84]. Two volumes of ice
cold methanol and 3 ng of deuterated LTB4 (d4-LTB4;
Enzo Life Sciences AG, Lausen, Switzerland) as internal
standard were added to 1 ml human milk. The samples
were centrifuged for 20 min at 2500 rpm and the super-
natant was diluted with 5 ml ultrapure water. The
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diluted supernatant was loaded on a C18 solid phase
extraction (SPE) column (Grace, Deerfield, IL, USA)
prewashed with 5 ml 90% methanol and 5 ml 5% metha-
nol. After sample loading, the SPE column was washed
with 2x5 ml 5% methanol and the analytes were eluted
with 3 ml 90% methanol. The eluate was dried under
nitrogen and redissolved in 100 μl 35% methanol (2 mM
ammonium acetate). The sample was filtered with a
0.2 μm syringe filter (BGB Analytik AG, Boeckten,
Switzerland) and 5 μl were injected into a HPLC-MS/MS
system. Calibration curves were obtained by lipid mediator
standard addition to human milk at the concentrations 0,
15, 30, 45, 60, 75 and 90 ng/ml.
HPLC-MS/MS of lipid mediators and hydroxy fatty acids
Analytes were separated using a HPLC system (UltiM-
ate® HPLC, LC Packings, Dionex, Olten, Switzerland)
with a C18 column (Luna 3u C18(2) 100A, 150x0.3 mm;
Phenomenex, Brechbühler AG, Schlieren, Switzerland).
A gradient was run over 10 min from 35% to 80%
methanol (2 mM ammonium acetate) and was kept con-
stant for 25 min at a flow rate of 4 μl/min. The column
was rinsed with 100% methanol and equilibrated with
35% methanol (2 mM ammonium acetate). Analytes of
interest were detected on a Sciex 4000 QTRAP mass
spectrometer (AB SCIEX GmbH, Zug, Switzerland) in
the negative ion mode. Several transitions per analyte
were scanned in multiple reaction monitoring mode and
are stated in (Additional file 1: Table S2). The transitions
used for quantification were 335→195 for LTB4,
351→115 for LXA4, 349→195 for RvE1, 375→233 for
RvD1, 343→281 for 17-HDHA, 317→167 for 18-HEPE,
319→175 for 15-HETE, 319→179 for 12-HETE and
339→197 for d4-LTB4. Fragments scanned for the bio-
active anti-inflammatory and pro-resolving LXA4, RvE1
and RvD1 were in agreement with prominent product
ions reported earlier [33,84-86]. The optimized MS
parameters were defined as: Electrospray ionization
(ESI), curtain gas (CUR) = 10, nebulizer gas (GS1) = 20,
auxiliary gas (GS2) = 0, ionspray voltage (IS) = −4500 V,
collision gas (CAD) = medium, entrance potential
(EP) = −10 V, cell exit potential = −11 to −5 V, dwell
time = 100 msec. Declustering potential (DP) and col-
lision energy (CE) were optimized individually for each
analyte (See Additional file 1: Table S2). Fragmentation
patterns for each analyte as standard substance as well as
isolated from human milk were obtained by product ion
scans at MS parameter settings defined above.
Data analysis
Statistical analysis was done using Microsoft Office
Excel. To estimate the difference between groups,
analysis of variance (ANOVA) with subsequent trend
analysis was used. All values are presented as mean with
standard deviation or as indicated. Two-sided p-values <
0.05 were considered significant.
Additional files
Additional file 1: Table S1. Extracted mass traces and working range
for fatty acid analysis. Table S2 Scanned transitions for lipid mediator
analysis. Table S3 Fatty acid precursors (% of total fatty acids) and
concentration (ng/ml) of corresponding hydroxy fatty acids and lipid
mediators in human milk over time of lactation.
Additional file 2: Figure S1. Fragmentation spectra of lipid mediator
standard substances and lipid mediators from human milk. Spectra were
obtained as product ion scans at collision energy specified in, Additional
file 1: Table S2 Quantifier and qualifier product ions selected for each
analyte are given in Additional file 1: Table S2 (A) Fragmentation of LTB4
standard and (B) LTB4 from human milk as products of 335 m/z; (C)
Fragmentation of LXA4 standard and (D) LXA4 from human milk as
products of 351 m/z; (E) Fragmentation of RvE1 standard and (F) RvE1
from human milk as products of 349; (G) Fragmentation of RvD1
standard and (H) RvD1 from human milk as products of 375. Rel. Int.,
Relative Intensity; m/z, mass per charge; Da, Dalton.
Additional file 3: Figure S2. Fragmentation spectra of hydroxy fatty
acid standard substances and hydroxy fatty acids from human milk.
Spectra were obtained as product ion scans at collision energy specified
in, Additional file 1: Table S2 Quantifier and qualifier product ions
selected for each analyte are given in, Additional file 1: Table S2 (A)
Fragmentation of 12-HETE standard and (B) 12-HETE from human milk as
products of 319 m/z; (C) Fragmentation of 15-HETE standard and (D)
15-HETE from human milk as products of 319 m/z; (E) Fragmentation of
18-HEPE standard and (F) 18-HEPE from human milk as products of 317;
(G) Fragmentation of 17-HDHA standard and (H) 17-HDHA from human
milk as products of 343. Rel. Int., Relative Intensity; m/z, mass per charge;
Da, Dalton.
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